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Key questions
What is already known about this subject?
 ► Analysis of tumour- derived DNA isolated from urine 
has been mainly applied to cancers of the urogenital 
tract. Few studies found KRAS alterations in urine 
trans- renal tumour DNA (trtDNA) of colorectal cancer 
patients using a quantitative mutation- enrichment 
next generation sequencing (NGS) method. These 
data were compared with archived tumour tissue 
and plasma circulating free tumour DNA (ctDNA) 
samples from patients with advanced metastatic 
colorectal cancer (mCRC), and it was observed a 
correlation between the molecular profile of trtDNAs 
and clinical outcomes.
What does this study add?
 ► We defined an optimised protocol to isolate trtDNA 
from urine and performed whole exome sequencing 
analysis of urine trtDNA as well as matched plasma 
ctDNA with tumour tissue of four mCRCs. We calcu-
lated genetic mutational concordance, estimated tu-
mour content and defined cancer- related mutational 
signatures. Most notably, we found that tumour- 
related genetic information is primarily present in 
low molecular weight trtDNA fragments.
How might this impact on clinical practice?
 ► Our method could improve the sensitivity and fea-
sibility of NGS technology. Urine trtDNA is a com-
pletely non- invasive test, which can complement 
blood- based ctDNA studies in screening out the 
general population to identify high risk individuals. 
As compared with blood, urine collection can be 
self- performed and, in principle, endlessly repeat-
ed, allowing more effective longitudinal monitoring 
of treatment response and minimal residual disease 
detection after surgery. Our study paves the way for 
using trtDNA in clinic; however, currently, trtDNA 
profiling is informative only in a small subset of col-
orectal cancer patients.
AbstrAct
Background The analysis of circulating free tumour 
DNA (ctDNA) in blood, commonly referred as liquid 
biopsy, is being used to characterise patients with solid 
cancers. Tumour- specific genetic variants can also be 
present in DNA isolated from other body fluids, such as 
urine. Unlike blood, urine sampling is non- invasive, can 
be self- performed, and allows recurrent longitudinal 
monitoring. The features of tumour DNA that clears from 
the glomerular filtration barrier, named trans- renal tumour 
DNA (trtDNA), are largely unexplored.
Patients and methods Specimens were collected 
from 24 patients with KRAS or BRAF mutant metastatic 
colorectal cancer (mCRC). Driver mutations were assessed 
by droplet digital PCR (ddPCR) in ctDNA from plasma and 
trtDNA from urine. Whole exome sequencing (WES) was 
performed in DNA isolated from tissue, plasma and urine.
Results Out of the 24 CRC cases, only four had sufficient 
DNA to allow WES analyses in urine and plasma. We 
found that tumour alterations primarily reside in low 
molecular weight fragments (less than 112 bp). In patients 
whose trtDNA was more than 2.69% of the urine derived 
DNA, cancer- specific molecular alterations, mutational 
signatures and copy number profiles identified in urine 
DNA are comparable with those detected in plasma ctDNA.
Conclusions With current technologies, WES analysis of 
trtDNA is feasible in a small fraction of mCRC patients. 
Tumour- related genetic information is mainly present 
in low molecular weight DNA fragments. Although the 
limited amounts of trtDNA poses analytical challenges, 
enrichment of low molecular weight DNAs and optimised 
computational tools can improve the detection of tumour- 
specific genetic information in urine.
IntRoduCtIon
Blood is the main source for the anal-
ysis of tumour biomarkers in patients with 
solid cancers. Serum proteins are routinely 
employed to track tumour burden in specific 
settings, but their clinical utility has inherent 
limitations including lack of specificity and 
sensitivity.1 On the other hand, plasma 
contains circulating tumour- derived nucleic 
acids and recent studies have indicated that 
they can be used for early detection,2 minimal 
residual disease quantification, tumour geno-
typing and molecular assessment of drug 
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resistance.3 4 Tumour- derived DNA (circulating free 
tumour DNA (ctDNA)) has also been identified in other 
body fluids, such as pleural effusions or cerebrospinal 
fluid of patients affected by thoracic or central nervous 
system tumours, respectively.5–8 However, the collection 
of these biospecimens, including blood, cannot be self- 
performed and requires dedicated equipment as well 
as trained personnel. Urine has been proposed as an 
alternate non- invasive and cost- effective source of cancer 
biomarkers, since urine collection can be self- performed 
and endlessly repeated (to monitor cancer progression 
and drug response) at any location and with a minimal 
effort. Fragments of urinary DNA originate either from 
urogenital tract cells, shedding during urine transit, or 
from circulating free DNA (cfDNA) passing through the 
glomerular barrier, which is also known as trans- renal DNA 
(trDNA). High molecular- weight (HMW) DNA fragments 
are usually over 1 kbp and are predominantly released 
into the urine by cells present in the genito- urinary tract, 
such as necrotic cells or lymphocytes.9–11 On the contrary, 
low- molecular- weight (LMW) DNA fragments, which are 
in the range of 10–200 bp, are though to derive from the 
blood- filtered ctDNA.9–11
The physiopathological mechanisms involved in the 
glomerular filtration of cfDNA and, hence, in the forma-
tion of LMW DNA (a.k.a trans- renal tumour DNA or 
trtDNA), have not yet been fully elucidated; although, 
it is known that the quantity of LMW DNA depends on 
the permeability of the basal membrane and on the slit 
membranes between podocytes pedicles during glomer-
ular filtration.
So far, urine has been mainly exploited for the analysis 
of biomarkers in patients affected by urological malig-
nancies.11 Studies of urinary cfDNA from cancer patients 
with non- urological tumours have been more limited 
and have mainly focused on the assessment of selected 
genetic alterations. Indeed, proof- of- concept studies 
revealed the possibility to use urine trtDNA to inform 
about the pharmacodynamics of tyrosine kinase inhibi-
tors in epidermal growth factor receptor (EGFR) mutant 
lung cancer patients.12 13 Similarly, in a case report study 
we found that tumour burden could be tracked in urine 
trtDNA by detecting a CAD- ALK gene rearrangement in a 
metastatic colorectal cancer (mCRC) patient treated with 
an ALK inhibitor.14 RAS mutations, which are routinely 
assessed in mCRC patients to guide treatment selection, 
could be also detected in urine trtDNA using a quanti-
tative, mutation- enrichment NGS method, and showed a 
good concordance with tumour tissue DNA or matched 
plasma ctDNA samples.15
All of the above studies employed urine cfDNA for 
assessing specific alterations, and it remains to be estab-
lished whether urinary cfDNA is sufficient to have a 
comprehensive characterisation of solid tumour geno-
typing. To our knowledge, the entire coding sequence of 
tumours from urine- derived DNA has not been previously 
reported. Here we describe how we improved the current 
protocols to determine the molecular landscape via whole 
exome sequencing (WES) analysis in urine trtDNA of 
four mCRC tumours, assessing their mutational concor-
dance between tissue, plasma and urine, calculating their 
tumour loads, and defining their cancer- related muta-
tional signatures.
MetHods
Patients
Patients were selected according to the following criteria: 
(1) patients had to have histologically confirmed diag-
nosis of mCRCs; (2) with a tumour burden defined as 
the sum of the longest diameters of tumour in at least 
three measurable lesions, higher than 2 cm in total; (3) 
availability of matched tissue in formalin- fixed paraffin- 
embedded (FFPE) or fresh tissue, blood, peripheral 
blood mononuclear cells (PBMC) and urine samples; (4) 
KRAS and BRAF positive mutational status in tissue was 
also required. Importantly, the patients should not have 
had any comorbidity in the urinary tract.
Using droplet digital PCR (ddPCR) analysis the concor-
dance for KRAS or BRAF mutations was 100% (24/24) 
between tissue and plasma.
Tumour specimens (FFPE), plasma and urine 
samples of 24 patients were collected from histologically 
confirmed mCRC patients, treated at Grande Ospedale 
Metropolitano Niguarda (NCC) or Istituto Nazionale 
Tumori (INT), Milan, Italy. Availability of tumour sample 
qualitatively and quantitatively suitable for molecular 
analyses was a requirement for being considered in the 
present study.
dnA isolation from FFPe, plasma and urine
Genomic DNA and plasma derived cfDNA were isolated 
from fresh tissue, FFPE and blood- isolated PBMC, as 
previously described.16
For trtDNA extraction, at least 100 mL of urine was 
concentrated to 4 mL using Vivacell 100 concentrators 
(Sartorius Corp) and incubated with 700 ul of Q- sep-
harose Fast Flow quaternary ammonium resin (GE 
Healthcare). We modified the previously used protocol 
for trtDNA isolation from urine and performed a double- 
step ultrafiltration to separate the low molecular weight 
from the high molecular weight fragments, and treated 
them as individual samples until the end of the proce-
dure.14 trtDNA fragment size distribution was assessed 
using the 2100 Bioanalyzer High- Sensitivity DNA assay kit 
(Agilent Technologies) according to the manufacturer’s 
instructions.
ddPCR analysis
Isolated cfDNA was amplified using ddPCR Supermix for 
Probes (Bio- Rad) with KRAS and BRAF assays (PrimePCR 
ddPCR Mutation Assay, Bio- Rad). ddPCR was then carried 
out according to the manufacturer’s protocol and the 
results were reported as percentage or fractional abun-
dance of mutant DNA alleles to total (mutant plus wild 
type DNA alleles).
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Figure 1 Stratification of patient cohort. Diagram showing 
study cohort of 24 patients from whom we obtained 
matched urine and blood samples gathered from two Italian 
institutions. Four out of five patients were analysed by WES 
analysis, two were positive for KRAS and two for BRAF 
mutations, one patient was filtered out due to failure to 
pass NGS quality check. CRC, colorectal cancer; ctDNA, 
circulating free tumour DNA; ddPCR, droplet digital PCR; 
HMW, high molecular weight; LMW, low molecular weight; 
WES, whole exome sequencing.
nGs library preparation
Libraries from PBMC and the fresh tissue available for 
CRC- UD09 patient were prepared starting from 100 up 
to 120 ng of extracted DNA by means of Nextera Rapid 
Capture Exome kit, according to manufacturer’s protocol 
and as previously described.16
For NGS on liquid biopsies from CRC patients, library 
preparation was performed using up to 150 ng of cfDNA 
from plasma or urine samples. cfDNA has been treated 
with NEBNext Ultra DNA Library Prep Kit for Illumina. 
For subsequent steps of library prep workflow, Nextera 
Rapid Capture Exome kit reagents have been used as 
previously reported.16
All libraries were sequenced on the Illumina NextSeq500 
sequencer (Illumina) and 150 bp paired end reads were 
generated.
Wes bioinformatic analysis
Genetic discovery analysis was performed using a previ-
ously described NGS pipeline designed for WES analyses 
of paired cancer genomes which identifies somatic varia-
tions, insertions and deletions (indels) and copy number 
alterations.7 16–18 Details on bioinformatics analysis are 
provided in online supplementary file 2.
The final median depth obtained was 210X (on 18 
WES), with more than 97.03% (see online supplemen-
tary file) of the targeted region covered (after filtering). 
Furthermore, only mutations with 5% significance level 
obtained with a Fisher test, supported with a minimum 
depth of 5X and at least 1% allelic frequency were 
considered.
Using the information of somatic single nucleotide vari-
ants, a series of mutational profiles were extracted and 
genetic signatures were calculated using MuSiCa tool.19
Data are available at the link: https://www. ebi. ac. uk/ 
ena/ data/ view/ PRJEB33785
Accession number: PRJEB33785.
Unique name: ena- STUDY- CANDIOLO CANCER 
INSTITUTE-31-07-2019-11:20:38:154–19.
Results
urine dnA differential isolation
To proceed with trtDNA analysis, we further improved a 
protocol we previously employed for urine trtDNA isola-
tion to enrich for tumour- derived DNA content. Specifi-
cally, we performed a double- step ultrafiltration to sepa-
rate LMW fragments from the HMW ones by treating 
the two fractions as individual sample until the end of 
the DNA isolation procedure (figure 1, online supple-
mentary figures S1 and S2). The new ultrafiltration step 
separated the majority of the LMW fragments from those 
longer than 400 base pairs. We found that this method 
avoids the massive DNA loss that is encountered with 
other techniques. All urine trDNA were isolated and 
tested with ddPCR (online supplementary table S1). In 
five cases out of 24 (20.8%) (online supplementary table 
S2), KRAS or BRAF mutations were identified in both 
urine and matched plasma (details are reported in online 
supplementary file 1, online supplementary tables S1 and 
S2). Therefore, only those five cases where considered for 
further analysis.
Prior to NGS, we performed a quality control to assess 
suitability of DNA for WES analysis. The case CRC- UD22 
failed our quality control and was excluded. For the other 
four cases (clinical characteristics reported in online 
supplementary table S2), WES was performed on DNA 
coming from urine, tissue, plasma, and matched PBMC 
samples. The germ- line WES was used as a reference for 
bioinformatics analysis (details are reported in online 
supplementary file 2). When the amount of DNA was 
conductive (cases CRC- UD24 and CRC- UD21), WES anal-
ysis was performed on both HMW and LMW enriched- 
fragments (cut- off: 400 bp) trtDNA fractions. In the case 
CRC- UD09 we only analysed the LMW- enriched compart-
ment, since there was not sufficient amount of DNA in 
the HMW one to perform WES, while for the case CRC- 
UD02, WES analysis was performed on the entire trtDNA 
recovered from the urine fluid because the recovered 
amount of HMW fragments was too low (figure 1 and 
online supplementary figure 2).
snPs, mutational concordance and tumour content analysis of 
matched plasma/urine samples in CRC patients
After verifying the coverage in all the sequencing runs 
(online supplementary table 3), we confirmed that the 
samples analysed belonged to the same cancer patient 
by comparing their single nucleotide polymorphisms 
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Figure 2 Tumour DNA content in matched tissue, 
plasma and urine samples from four CRC patients. Pie 
charts showing tumour content measured using fractional 
abundance of driver alterations: BRAF p.V600E mutation 
for cases CRC- UD09 and CRC- UD21, KRAS p.G13D and 
p.G12D, respectively for CRC- UD24 and CRC- UD02. 
Number indicates mutational frequency of the gene 
molecular alteration used to calculate tumour content. CRC, 
colorectal cancer; ctDNA, circulating free tumortumour 
DNA; gDNA: genomic DNA; trtDNA, trans- renal tumour 
DNA.
(SNPs, dbSNP V.147). In all cases the allelic matching was 
confirmed (online supplementary table 4).
We next identified trunk alterations (i.e., KRAS or BRAF 
mutations) in tissue genomic DNA (gDNA) in all four 
mCRC cases and used them to estimate the tumour DNA 
content in each sample (figure 2). We then established 
the level of concordance between the alterations detected 
in urine and in matched plasma samples. For this anal-
ysis we examined all the molecular alterations detected 
in matched tumour tissue and we obtained a value of 
genetic concordance between plasma and urine (defined 
as mutation positivity for the alterations confirmed in 
tumour tissue), ranging from 27.9% to 57.4% (figure 3A, 
B), which we found to be influenced by the tumour 
DNA content in each liquid specimen. In detail, CRC- 
UD24 and CRC- UD09 had high tumour DNA content in 
plasma, but low in the matched urine (figure 2A), while 
the cases CRC- UD21 and CRC- UD02 had a comparable 
tumour DNA content in both urine and matched plasma 
samples (figure 2B).
Indeed, when tumour DNA content was low and closer 
to the WES limit of detection (nearly 1%), the amount of 
variations identified varied noticeably. In fact, in the first 
two cases (CRC- UD24 and CRC- UD09), the number of 
detected variations in the urine trtDNAs were few, 40/89 
mutations (44.9%) and 41/147 mutations (27.9%), as 
well as total tumour DNA content which was 2.7% and 
3.7%, respectively (figure 2A and figure 3A). In the 
second group (CRC- UD21 and CRC- UD02) the total 
number of mutations identified in urine, 6.15% and 
15.4%, was comparable to the one found in the plasma, 
6.7% and 5.8% (figure 2B). This led to an increased 
number of shared somatic mutations between the two 
specimens: 27/47 mutations (57.4%) in CRC- UD21, and 
49/89 mutations (55.4%) in CRC- UD02 (figure 3B).
Copy number alterations, mutational profiles and signature 
analysis in matched plasma and urine samples
Overall, the copy number profiles in plasma and urine 
samples were comparable. However, we noticed that a 
case (CRC- UD09) displayed an increased copy number 
of the chromosome seven in the plasma ctDNA sample, 
but not in the matched urine (online supplementary 
figure 3). This discrepancy might be due to the different 
tumour content, which was much lower (3.73%) in the 
urine compared with the matched plasma (47.51%) 
(figure 2A).
We defined mutational signatures as combinations of 
types of mutations resulting from mutagenesis processes 
such as variations in DNA replication, DNA enzymatic 
editing, exposures to DNA damaging agents and tissue 
culture conditions. Thus, we characterised the muta-
tional signatures of the four mCRC patients in the plasma 
ctDNA and matched urine trtDNA samples, identifying in 
the plasma as well as in the urine samples a combination 
of signatures 1, 6 and 10 (online supplementary figure 
4). Overall there was high concordance between signa-
tures present in urine and plasma (online supplementary 
figure 5).
Next, we compared the mutational profile obtained 
from high and low- enriched molecular weight DNA 
fragments in the cases CRC- UD24 and CRC- UD21 and 
observed a higher similarity in the genetic profiles 
between the plasma and urine LMW- enriched DNA 
fragments (figure 4A,C). This confirmed our previous 
observations.
Finally, we calculated the G parameter, defined as the 
sum of the squares of the differences of each signature 
between plasma and HMW- enriched (G=0.06475 and 
G=0.069799, respectively) as well as between plasma and 
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Figure 3 Concordance analysis of matched plasma/urine samples in CRC patients. Mutations found in the tumour tissue 
and in both matched plasma and urine ctDNA are shown. ‘Concordance’ indicates the number of somatic mutations shared 
between plasma and urine samples. For cases CRC- UD21 and CRC- UD24, the average frequency of each mutation identified 
in two urine samples is reported. Coloured- scale is used to show fractional abundance for each mutation. (A) Cancer patients 
with low tumour content identified in urine ctDNA. (B) Cancer patients with high tumour content identified in urine ctDNA. 
CRC, colorectal cancer; ctDNA, circulating free tumour DNA; trtDNA, trans- renal tumour DNA.
LMW- enriched (G=0.04969 and G=0.052517, respec-
tively). In both CRC- UD24 and CRC- UD21 the genetic 
similarity between the LMW- enriched urine and the 
matched plasma was higher than that identified in HMW- 
enriched DNA fragments (figure 4B,D).
tumour-specific alterations occur more frequently in shorter 
reads
In the cases CRC- UD24 and CRC- UD21, in which we 
were able to analyse the low and high- enriched molecular 
weight fragments, separately, we sought to differentiate 
the molecular variations identified in the HMW- enriched 
and LMW- enriched DNA fragments in urine sample 
(figure 5A,D) as well as in the matched tumour tissue and 
plasma. A concordance of 40/89 mutations (45%) and 
25/89 mutations (28%) was obtained in LMW- enriched 
and HMW- enriched DNA fragments, respectively 
(figure 5B). This confirms an enrichment of DNA from 
tumour origin in the low molecular weight DNA frag-
ments, as also shown by the average read lengths analysis 
(figure 5C).
In CRC- UD21 we obtained a concordance level of 22/47 
(46%) in LMW- enriched and of 27/47 (57%) in HMW- 
enriched DNA (figure 5E) due to a minor enrichment of 
short fragments for DNA of tumour origin (figure 5F).
Intrigued by these results, we tested whether there 
were any differences in DNA fragments length shed by 
tumour cells (therefore carrying mutated reads) and 
those originated from normal cells (wild type reads). To 
formally test this, we used NGS data and compared the 
read length of the urine fragments with or without the 
mutations previously identified in the primary tumours. 
We observed a significant difference (Wilcoxon rank test, 
p value <0.00001) between the tumour DNA fragments 
lengths in plasma (figure 6) of six bases (190 bp vs 196 bp, 
respectively).
We then performed the same analysis on the DNA frag-
ments derived from the urine and observed again a differ-
ence (Wilcoxon rank test, p value <0.00001) of 31 bases 
(112 bp vs 143 bp) between the tumour read lengths in 
urine as compared with their WT counterpart, confirming 
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Figure 4 Signature and mutational profiles of samples enriched for high and low molecular weight fragments. (A) and (C) 
Mutational profiles of enriched HMW and LMW urine samples and matched plasma ctDNA for cases CRC- UD24 (left) and 
CRC- UD21 (right). (B) and (D) Signature enrichment of HMW- enriched and LMW- enriched urine samples and matched plasma 
ctDNA is shown. Dendrogram is shown on the top, with a percentage indicating the similarity of each of the 30 signatures to 
the samples shown in the centre, while the G parameter (below the arrows) indicates the sum of the squares of differences 
between each signature observed in plasma ctDNA and the matched signatures in enriched HMW and LMW urine trtDNA 
samples. CRC, colorectal cancer; ctDNA, circulating free tumour DNA; HMW, high molecular weight; LMW, low molecular 
weight; trtDNA, trans- renal tumour DNA.
our initial observation that tumour- specific alterations 
occur more frequently in shorter reads (figure 6).
dIsCussIon
ctDNA isolated from various body fluids has been 
exploited as a novel biomarker in the clinical manage-
ment of cancer patients.3 In this context, urine has great 
advantages: it is completely non- invasive and easily acces-
sible, it requires no specialised facility or equipment for 
collection, which makes urine highly convenient and a 
cost- effective biomarker source. Blood collection, on the 
contrary, can be limited in term of accessibility, frequen-
cies, and volume drawn for ethical or clinical reasons, 
limiting real time patient monitoring.
We and others previously evaluated the concordance 
between molecular tumour alterations in urine- derived 
trtDNA, tumour tissue and plasma.15 20 These studies 
included KRAS mutations and gene fusions assessments 
in CRC, BRAF mutations in histiocytic disorders, and 
EGFR mutations in non- small cell lung cancer.21
The paucity of urine- based liquid biopsy studies might be 
explained by the limitations of this sample ctDNA source 
being more diluted by non- tumoural cfDNA. Consequently, 
more sensitive assays are mandatory for trtDNA detection.
In the present study, to obtain a molecular portrait of 
the patients’ DNA with maximum sensitivity to biologically 
profile DNA characteristics, we modified the previously 
used protocol for trtDNA isolation from urine14 with a 
double- step ultrafiltration, allowing an enrichment of low 
molecular weight fragments. Such concentration of the 
LMW- enriched DNA fragments was shown to increase the 
sensitivity towards DNA from tumour origin.20 In fact, Su 
and colleagues used a size- selection based on magnetics 
beads which in our hands (data not shown) was associ-
ated with loss of material during the washes. Therefore, 
we recommend a size- selection via dual steps centrifuga-
tion which, despite being less efficient in selecting frag-
ments, was able to maintain a very high recovery rate.
Interestingly, two patients (CRC- UD24 and CRC- UD09) 
had high tumour DNA content in plasma, but low in the 
matched urine, while other two cases (CRC- UD21 and 
CRC- UD02) had a comparable tumour DNA content in 
both urine and matched plasma samples.
We hypothesize that the higher tumour burden, detected 
in plasma ctDNA in the cases CRC- UD24 and CRC- UD09, 
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Figure 5 Low molecular weight (LMW) DNA fragments in urine samples are enriched in tumour content. (A) and (D) 
Distribution of DNA fragment lengths in urine sample processed to enrich high molecular weight fragments (HMW in purple, 
on the left) from low molecular weight fragments (LMW in red, on the right) before sequencing. (B) and (E) Mutations found 
in plasma ctDNA and matched urine when enriched for high and low molecular weight DNA fragments. Only mutations also 
found in the matched tumour tissue are shown. The concordance frequency (%) was calculated on the number of shared 
variations identified in both plasma and urine ctDNA on the total number of variations identified. Blue- coloured scale indicates 
different fractional abundances reported for each mutation. (C) and (F) DNA fragments’ length distribution in urine trtDNA 
sample enriched for HMW and LMW. Data were obtained by measuring all reads lengths sequenced and aligned to the human 
genome reference V.19. CRC, colorectal cancer; ctDNA, circulating free tumour DNA.
could be due to the plasma ctDNA from blood, which was 
not entirely filtered by the kidney barrier (i.e., long DNA 
fragments and DNA from necrotic cells did not go through 
the glomerular capillaries). This resulted in an overall 
reduction of tumour- derived DNA quantity in the urine, as 
effectively detected. Furthermore, the differential amount 
of DNA released from the cells of the urinary tract (which 
conceivably could be individual- specific) could also have 
affected the dilution effect on tumour- derived DNA frag-
ments. This could have influenced (positively or negatively) 
the detection of tumour- specific molecular alterations. It is 
reasonable to believe that these two scenarios could vary 
among different individuals or different collection time-
points in the same subject. This could explain why the 
cases CRC- UD21 and CRC- UD02 had comparable tumour 
contents (tumour DNA fragments) in the plasma and 
matched urine fluid.
We speculate that although the urine trtDNA is a result 
of the glomerular filtration of the plasma ctDNA, this 
phenomenon could be due to our urine isolation protocol 
which selects and enriches for the low- molecular weight 
fragments.
We also wanted to highlight that we collected first- morning 
void urine for DNA extraction and analysis, following the 
gold standard protocol for urine analysis. However, it would 
be reasonable to argue that the first- morning void urine 
(which has been in contact with the bladder overnight) 
might contain higher amount of normal DNA from urothe-
lium cells, contributing to the dilution of the tumour- 
derived fragments. However, in another case, UD- CRC21, 
the (double- step DNA) isolation procedure did not result 
in an efficient DNA fragment separation, influencing our 
mutational calling capabilities.
Most importantly, we found that tumour mutations 
are mainly supported by shorter reads. This evidence 
emerged due to the improved NGS- computational 
pipeline we developed which allowed us to observe that 
tumour- derived DNA is mainly present in low molecular 
weight fragments. This finding has implications for future 
studies that aim to improve the sensitivity of trtDNA 
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Figure 6 Tumour- specific alterations occur more 
frequently in shorter reads. Distributions of mutated reads 
(tumour, red) and wild type reads (normal, blue) are shown 
in boxplots. For each somatic mutation of four patients, 
the reads encompassing somatic mutations were used to 
calculate the distributions of lengths. N depicts the total 
number of reads used to calculate the distributions for 
both plasma and urine trtDNA samples. trtDNA, trans- renal 
tumour DNA.
analysis and opens unprecedented opportunities for 
early detection, therapy monitoring and measurement of 
minimal residual disease after surgery.
In conclusion, this study is a proof of concept that clearly 
showed the feasibility of the use of urine samples for genetic 
profiling of non- urogenital tract tumours, mCRC patients. 
Moreover, we found that DNA fragments of low molecular 
weight are preferentially derived from tumour cells, high-
lighting the relevance of developing protocols that improve 
their isolation to increase the recovery rate of these frag-
ments. While urine- based liquid biopsy is promising and 
has potential advantages over blood- based tests, additional 
technical improvements are required before entering as a 
routine text in clinic to monitor the genotype of tumours 
originating not in the urogenital tract.
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